EMA Authorised: Elahere (mirvetuximab soravtansine) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The European Medicines Agency authorised Elahere (mirvetuximab soravtansine) for ovarian cancer, fallopian tube cancer and peritoneal cancer, with AbbVie Deutsc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Elahere (mirvetuximab soravtansine)

Snippet

Status: Authorised. Therapeutic area: Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 22/01/2026. Orphan medicine